Market Overview
Global Iron Dextran Injection market was valued at USD 5085 million in 2024 and is projected to reach USD 6940 million by 2031, exhibiting a CAGR of 4.7% during the forecast period. This steady growth reflects the increasing demand for effective iron deficiency treatments across both human and veterinary applications.
Iron dextran injection is a parenteral iron therapy formulation consisting of a complex of iron hydroxide with dextran polymers. It is primarily used to treat iron deficiency anemia when oral supplementation is ineffective or contraindicated. The formulation enables controlled release of iron while minimizing toxicity risks, making it particularly valuable for patients with chronic kidney disease, inflammatory bowel disorders, or malabsorption syndromes.
USD 5085 million in 2024
USD 6940 million by 2031
of 4.7%
Veterinary Use Segment Dominates the Market Due to Extensive Application in Livestock and Animal Health
Management
The market is segmented based on type into:
Human Use
Subtypes: Low molecular weight iron dextran and high molecular weight iron dextran
Veterinary Use
Iron Dextran Injection for human use is primarily administered to address anemia in patients with chronic kidney disease or those undergoing dialysis, where oral iron supplements may be insufficient. This segment benefits from growing awareness of nutritional deficiencies in developed regions. In contrast, the veterinary use segment leads the market owing to its widespread adoption in agriculture for preventing anemia in pigs, cattle, and other livestock, supporting global food production needs. The dominance of veterinary applications stems from the scale of animal husbandry operations, particularly in emerging economies where iron supplementation enhances animal growth and productivity.
By Application
The market is segmented based on application into:
Hospital
Pharmacy
Other
The hospital application segment holds a prominent position as Iron Dextran Injections are frequently used in inpatient and outpatient settings for rapid correction of severe iron deficiencies, especially in cases involving blood loss or malnutrition. Pharmacies contribute through retail distribution for outpatient prescriptions, catering to patients requiring ongoing therapy. The "other" category encompasses specialized uses in clinics, veterinary practices, and research facilities. Overall, the hospital segment's leadership is driven by the need for immediate intravenous administration under medical supervision, aligning with the rising incidence of anemia linked to chronic diseases and improving access to healthcare infrastructure worldwide.
Portable Neuromonitoring Device Market
https://www.24lifesciences.com
Our Key Players
Pharmacosmos A/S (Denmark)
Vetoquinol (France)
Bimeda (Ireland)
Swiss Parenterals (India)
Acino Pharma (Switzerland)
Bimeda (Ireland)
